ArticleAnnals of nuclear medicine2026
Outcome of MRI-Guided Single-Dose Iodine-131 for Graves' Hyperthyroidism with Large Goiter.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveSurgery is recommended over radioactive iodine-131 therapy (RIT) for Graves’ hyperthyroidism (GH) with large goiter (LG, thyroid volume [TV] ≥ 80 mL). Historically, inaccurate volumetry and insufficient activity yielded low success rates. We aimed to evaluate the efficacy and safety of magnetic resonance imaging (MRI)-guided calculated-activity RIT in LG versus non-LG patients and to identify RIT failure risk factors.
methodsGH patients receiving calculated-activity RIT (July 2017 to September 2024) were included, excluding those with prior RIT or incomplete data. TV was measured on MRI. Success included overt/subclinical hypothyroidism, euthyroidism, or subclinical hyperthyroidism. Failure included repeat RIT, surgery, or overt hyperthyroidism. Follow-ups ended at second RIT, surgery or March 2025. Risk factors for RIT failure were identified through Firth’s penalized logistic regression and least absolute shrinkage and selection operator.
resultsAmong 181 patients with GH (mean age, 37.5 ± 13.7 years, 48 men), 33 had LG (mean TV, 146.6 mL). Minor adverse events were observed in LG patients (head-neck swelling [6.1%], exophthalmos progression [3.0%] and new-onset [3.0%]). Success rates were similar (LG 84.8% vs. non-LG 91.9%; P = .36), with universal goiter reduction. Planned activity-to-TV ratio (PA/TV) (odds ratio [OR], 0.68; 95% CI, 0.45–0.94; P = .02), and age (OR, 1.05; 95% CI, 1.01–1.10; P = .01) predicted RIT failure. Planned activity increased with TV in RIT success patients.
conclusionsWith mild adverse events, MRI-guided calculated-activity RIT achieved comparable success in LG and non-LG GH patients. Insufficient PA/TV, but not TV itself, was associated with RIT failure.
Indexed as
Identifiers
41706371What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.